Fig. 6

Co-treatment with HTGT and EMIQ protected mice from high-fat diet-induced obesity. A Schematic diagram of experimental design and treatment schedule. B Body weight monitoring of high-fat diet (HFD) fed mice treated with vehicle control (CTL), mirabegron (Mira, 10 mg/kg) and combination of HTGT and EMIQ (H + E, 100 mg/kg each) (n = 6). C Body weight change of HFD fed mice treated with vehicle control (CTL), mirabegron (Mira, 10 mg/kg) and combination of HTGT and EMIQ (H + E, 100 mg/kg each) during 2 weeks of treatment (n = 6). D Body composition of fat and lean of HFD fed mice treated with vehicle control (CTL), mirabegron (Mira, 10 mg/kg) and combination of HTGT and EMIQ (H + E, 100 mg/kg each) (n = 6). E Hematoxylin and eosin (H&E) staining of brown adipose tissue (BAT), inguinal white adipose tissue (iWAT) and gonadal white adipose tissue (gWAT) obtained from HFD fed mice treated with vehicle control (CTL), mirabegron (Mira, 10 mg/kg) and combination of HTGT and EMIQ (H + E, 100 mg/kg each) (Size bar = 50 μm) (n = 6)